CollPlant Biotechnologies Ltd. beat EPS estimates 17% of the time across 18 reported quarters (3 beats, 15 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | — | $-0.28 | — | Miss |
| Q12026 FY2026 | — | $-0.23 | — | Miss |
| Q42025 FY2025 | $-0.19 | $-0.67 | -252.6% | Miss |
| Q42025 FY2025 | $0.38 | $-0.27 | -171.1% | Miss |
| Q32025 FY2025 | $-0.10 | $-0.28 | -180.0% | Miss |
| Q22025 FY2025 | $-0.37 | $-0.13 | +64.9% | Beat |
| Q12025 FY2025 | $-0.42 | $-0.34 | +19.1% | Beat |
| Q42024 FY2024 | $-0.28 | $-0.38 | -35.7% | Miss |
| Q32024 FY2024 | $-0.35 | $-0.37 | -5.7% | Miss |
| Q12024 FY2024 | $-0.35 | $-0.42 | -20.0% | Miss |
| Q42023 FY2023 | $-0.07 | $-0.24 | -242.9% | Miss |
| Q42023 FY2023 | $-0.13 | $-0.38 | -192.3% | Miss |
Back to CLGN overview · CLGN holders · CLGN KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.